Skip to main content

Advertisement

SpringerLink
Log in

Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD

  • Letter to the Editor
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Results from seven studies of four subcutaneous IgG preparations in patients with primary immune deficiencies show that the incidence of infection is inversely related to the steady-state IgG level. Maintaining higher IgG levels may be beneficial, and no given level is necessarily adequate for all patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28:779–802.

    Article  PubMed  Google Scholar 

  2. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105–16.

    Article  PubMed  CAS  Google Scholar 

  3. Bhole MV, Burton J, Chapel H. Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy. Immunol Allergy Clin North Am. 2008;28:821–32.

    Article  PubMed  Google Scholar 

  4. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008;28:803–19.

    Article  PubMed  Google Scholar 

  5. Thepot S, Malphettes M, Gardeur A, Galicier L, Asli B, Karlin L, et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG Levels. J Clin Immunol. 2010;30(4):602–6.

    Article  PubMed  CAS  Google Scholar 

  6. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139:133–41.

    Article  PubMed  CAS  Google Scholar 

  7. Desai SH, Chouksey A, Poll J, Berger M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J Allergy Clin Immunol. 2009;124:854–6.

    Article  PubMed  CAS  Google Scholar 

  8. Jolles S, Bernatowska E, De Gracia J, Borte M, Cristea V, Peter HH, et al. Efficacy and safety of IgPro20 in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clinical Immunology, 2011 (in press)

  9. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125:1354–60.

    Article  PubMed  CAS  Google Scholar 

  10. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.

    Article  PubMed  CAS  Google Scholar 

  11. Quinti I, Sorensina A, Guerra A, Rondell R, Spadaro G, Agonstini C, et al. Effectiveness of immunoglobulin replacement therapy in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011. doi:10.1007/s10875-011-9511-0.

    Google Scholar 

  12. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.

    Article  PubMed  CAS  Google Scholar 

  13. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–73.

    Article  PubMed  CAS  Google Scholar 

  14. Hagan JB, Fasano MB, Spector S, Wasserman R, Melamed I, Rojavin MA, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30:734–45.

    Article  PubMed  CAS  Google Scholar 

  15. Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518–26.

    Article  PubMed  CAS  Google Scholar 

  16. Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol 2011 (in press)

  17. Berger M, Murphy E, Riley P, Bergman GE, VIRTUE Trial Investigators. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin. G S Med J. 2010;103:856–63.

    Article  Google Scholar 

  18. US Food and Drug Administration. Guidance for industry: safety, efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Available at: http://www.fda.gov/cber/gdlns/igivimmuno.htm

  19. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122:210–2.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The author wishes to thank Dr. Henry Foehl for performing the statistical analysis.

Conflict of interest statement

Dr. Berger is a salaried employee of CSL Behring, LLC, with equity.

Author information

Authors and Affiliations

  1. CSL Behring LLC, 1020 First Ave, King of Prussia, PA, 19406, USA

    Melvin Berger

Authors
  1. Melvin Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melvin Berger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berger, M. Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD. J Clin Immunol 31, 924–926 (2011). https://doi.org/10.1007/s10875-011-9546-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-011-9546-2

Keywords

Search

Navigation